Patient access group criticizes poor coverage for cholesterol drugs

28 April 2017

US advocacy group The Institute for Patient Access (IfPA) has criticized insurers for denying coverage for advanced cholesterol-lowering drugs known as PCSK9 inhibitors.

The market for drugs of this type is currently led by Repatha (evolocumab) from US biotech Amgen (Nasdaq: AMGN) and Praluent (alirocumab) from Regeneron (Nasdaq: REGN) and Sanofi (Euronext: SAN).

The IfPA released data from the 12 months up to July 2016, showing that out of 80,775 claims, there were a total of 34,459 rejections, or 43%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK